This website uses cookies

Read our Privacy policy and Terms of use for more information.

Clinical Takeaway
DomainKey FindingEvidence Level
Children 6 to 11Semaglutide lowered BMI 13.5% over 68 weeks; on placebo it rose 2.7%. Over 2 years, treated children grew 4.4 cm a year, against 5.6 cm on placebo.1Phase 3 RCT, n=167. Not FDA-approved for obesity under 12
Teens 12 to 17Tirzepatide lowered BMI 18.5% over 72 weeks, against a 0.5% rise on placebo.2Phase 3 RCT, n=160. Not FDA-approved for obesity under 18
DoseCagriSema at 1.0 mg each produced 18.6% weight loss, against 4.6% on placebo. The lower doses were never compared directly with the 2.4 mg dose.3Phase 3b RCT, n=309
Phentermine8.2% weight loss vs 4.6% on placebo at 1 year, and 6.2% vs 4.7% at 2 years. Systolic blood pressure was similar; resting heart rate was about 3 beats a minute higher.4NIH-funded RCT, n=870. Presented, not yet published
MuscleSupervised lifting 3 days a week on tirzepatide cut lean loss by 1.09 kg and raised strength. It did not prevent the loss.5RCT, n=120
Function after 65On semaglutide alone, 11 of 26 older adults lost 10% or more of their stair-climb power in 16 weeks. Losing weight lowers that score even when the climb is no slower.6Post hoc, sponsor-run. Hypothesis only
Where it fitsShow families the growth data with the BMI data, treat the top dose as optional, and measure function in older patients, not just weight.My read

If a parent asked me about semaglutide for a 6-year-old with severe obesity, I’d want to show them 2 figures from ObesityWeek. One is how much the children’s BMI changed. The other is how fast they grew.

Sponsored · Newsletter brought to you by MicroVitamin+
MicroVitamin+ Mixed Berry tub beside a berry smoothie. Made in USA with imported ingredients. Rated 4.7/5 from 160+ reviews.
Multivitamin, creatine and collagen in one scoop
A lot of people end up with a multivitamin, a tub of creatine and a tub of collagen on the shelf. MicroVitamin+ puts them in one scoop, and it's cheaper than buying them separately.
Get 10% off your first order →
Use code DRMIKE at checkout.
I earn a commission on purchases made through this link or code. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The 6-year-old

Both figures come from STEP Young, which was published in the New England Journal of Medicine the day it was presented. The trial enrolled 167 children aged 6 to 11 and assigned them 2 to 1 to weekly semaglutide or placebo, with lifestyle counseling for every family. The average child was 10, and most had severe obesity.1

At 68 weeks, BMI had fallen 13.5% with semaglutide and risen 2.7% with placebo. Across the 2 years of the trial, the children on semaglutide grew an average of 4.4 cm a year and those on placebo 5.6 cm. Pubertal stage and bone age changed by about the same amount in both groups while the trial ran.1

I’d tell a parent that I can’t yet say what that growth difference means. Children with obesity often grow faster than their peers before puberty, and the investigators raise the possibility that some of the gap is growth settling toward a typical pace as BMI falls.1 That is a hypothesis. Nobody has followed these children to adult height, and until someone does, I’d put the growth chart next to the BMI chart at every visit.

Side effects were common. Vomiting was reported in 70% of the children on semaglutide and 29% of those on placebo at some point during the trial, although only 1 child stopped the drug because of gastrointestinal symptoms.1 The placebo group deserves a look for another reason. Children who received counseling alone kept gaining, which means that declining treatment is also a choice with a trajectory.

A day earlier, SURMOUNT-ADOLESCENTS reported tirzepatide in 160 teenagers.2 Here is how the pediatric trials line up.

Pediatric trials · Change in BMI, drug vs placebo
STEP Young1
Semaglutide, ages 6 to 11, 68 weeks
−13.5% vs +2.7%
SURMOUNT-ADOLESCENTS2
Tirzepatide, ages 12 to 17, 72 weeks
−18.5% vs +0.5%
STEP TEENS (2022)7
Semaglutide, ages 12 to 17, 68 weeks
−16.1% vs +0.6%
Primary analyses from each journal report. Separate trials of different drugs, not a head-to-head comparison.

You will see bigger numbers than these. Novo Nordisk’s announcement leads with a 17.4% reduction for the younger children,8 and Lilly gives 21.4% for the teenagers.9 Those come from an analysis that estimates what would have happened if every participant had stayed on treatment. The journals’ main results count everyone who was randomized, including the children who stopped. When a parent asks, I’d quote the journal’s number.

Neither drug is FDA-approved to treat obesity at these ages. Semaglutide’s obesity indication starts at 12 and tirzepatide’s at 18. Parents will be asking well before any regulator answers.

The 1959 pill

Phentermine has been on the US market since 1959 and is still labeled for short-term use, largely because nobody had run a long placebo-controlled trial. The NIH-funded LEAP trial did. It randomized 870 adults to phentermine 24 mg a day or placebo for 2 years, with an online lifestyle program for everyone.10

I’ve wanted better long-term data on phentermine for years. LEAP finally gives me a number I can use when a patient’s insurance won’t cover a GLP-1. At 1 year, people taking phentermine had lost 8.2% of their starting weight, compared with 4.6% on placebo.4 By 2 years, it was 6.2% versus 4.7%. I’d still discuss an inexpensive generic with the right patient. I’d also tell them how much that gap narrowed.

The safety findings need the same care. Systolic blood pressure was similar in the 2 groups throughout, and at 2 years resting heart rate was about 3 beats a minute higher with phentermine.4 LEAP excluded people with heart disease,11 and blood pressure was well controlled when participants enrolled,12 so the trial can’t speak for patients with cardiovascular disease. The results were presented at the meeting and haven’t been published or peer reviewed. Nothing here changes the label, and phentermine remains a controlled substance.

Patients who are losing weight on a middle dose often ask me some version of this: “If I’m doing well on this dose, what do I gain by going up?” REDEFINE 9 is the closest thing to an answer for CagriSema, Novo Nordisk’s investigational combination of cagrilintide and semaglutide. It tested 1.7 mg and 1.0 mg of each component, well under the 2.4 mg used in the earlier phase 3 program. Counting everyone who was randomized, whether or not they stayed on the drug, weight loss at 68 weeks was 19.4% at the 1.7 mg dose and 18.6% at the 1.0 mg dose, against 4.6% on placebo.3

Neither dose was compared directly with 2.4 mg. In REDEFINE 1, a separate trial, the 2.4 mg dose produced 20.4% on the same kind of analysis.13 That makes the lower doses look close, but a comparison across trials can’t show that they are equivalent. What REDEFINE 9 does show is that a patient can lose close to a fifth of their body weight without reaching the top of the titration ladder.

Stepping down after the weight is already off is a separate question, and SURMOUNT-MAINTAIN is the trial that answers it. People who stepped down from their maximum tirzepatide dose to 5 mg held a 16.6% weight loss at 112 weeks, compared with 21.9% for those who stayed at the maximum dose and 9.9% for those switched to placebo.14 The lower dose gave back some of the loss and kept far more of it than stopping did. When a patient’s coverage falls through, that is the option I’d put on the table first.

In a session built around the new JAMA Summit report on obesity, Louis Aronne of Weill Cornell said that more than half of his patients can’t get an obesity medication covered. “Care has to start with coverage,” he said.15,16 Until that changes, finding the lowest effective dose is a clinical skill, not a compromise.

Also on the program · 3 headlines to handle with care
1.“Retatrutide cut knee pain by up to 76%.”
Against placebo, the gain was 1.4 to 1.8 points on a 10-point scale, because placebo patients improved by about 2 points on their own.17 A real benefit, and a smaller one than the headline.
2.“Retatrutide cut sleep apnea events by up to 61%.”
Against placebo, the difference was 22 to 24 fewer events an hour among 243 people with sleep apnea.18 The drug is investigational, and in the knee trials up to 18% of patients on the 12 mg dose stopped for adverse events.17
3.“23.3% weight loss in type 2 diabetes.”
Eloralintide plus tirzepatide, in a phase 2 trial.9 Between 11% and 27% of patients on the combination stopped for adverse events, against 3% on tirzepatide alone. I covered it in October.
Free download
Want the published GLP-1 trials on one page before the next wave lands? The GLP-1 Evidence Cheat Sheet puts 12 of them side by side.
Get the free cheat sheet

The flight of stairs

On the Monday of the meeting, 2 sessions running in the same hour took up the same fear from opposite ends: that GLP-1 drugs strip muscle.

In the first, Brandon Roberts of Walter Reed made the reassuring case.19 Roughly a quarter of the weight lost on any diet is lean tissue, a benchmark that predates these drugs,20 and by his calculations the modern trials land close to it. In a French cohort treated with semaglutide, grip strength rose by 4.5 kg over 12 months even though lean mass fell early on.21

He then turned to T-REx, published a week before the meeting. All 120 adults took tirzepatide for 40 weeks, and half were assigned to resistance training: 3 supervised sessions a week at an exercise center, about an hour each, with the loads increased as people got stronger. They attended 91% of those sessions. Both groups lost about 22 kg. The lifters lost 3.57 kg of lean tissue against 4.67 kg in the drug-only group. The result I keep coming back to is strength. On the knee-extension test, the lifters gained 5.9 kg while the drug-only group lost 4.4 kg.5 People assigned to lift got stronger even as they lost some lean tissue.

John Jakicic of the University of Kansas used the question period to correct the language, and he was right to. Resistance training attenuated the loss of lean tissue; it did not maintain it. The paper’s own title says “attenuate,” and the posts calling T-REx proof that lifting preserves muscle on a GLP-1 are describing a different result.

The other session was less comfortable. Veru, the company developing the selective androgen receptor modulator enobosarm, presented a post hoc analysis of its phase 2b QUALITY trial, in which adults 60 and older taking semaglutide also received enobosarm or a placebo for 16 weeks. Among participants 65 and older on semaglutide alone, 11 of 26 lost at least 10% of their stair-climb power. None of the 26 on enobosarm 3 mg did.6

There’s a wrinkle in that number. Body weight is part of the stair-power calculation. You can lose weight, climb the same flight in the same time, and get a lower score.

Add that this is a small, after-the-fact analysis run by the company that would sell the fix, in a drug class with a troubled history outside of trials, and I wouldn’t prescribe on it. I wouldn’t dismiss it either, because the 2 sessions were describing different things. Roberts is right about the average: the share of weight lost as lean tissue on these drugs is about what dieting has always produced. The stair data are about the tail, the 70-year-old who starts with little reserve and may lose some of it in 4 months. An average can be ordinary while the person in front of you is not.

David Church of the University of Arkansas gave the most usable talk of the hour, and his take-home slide put it in bold: protect function, not just mass.19 The protein RDA of 0.8 g/kg was built to prevent deficiency, not to carry someone through a large energy deficit. In the data he showed from older adults with obesity, it took about twice the RDA to bring whole-body protein balance above zero. For patients well over 100 kg, he suggested dosing by lean or adjusted body weight, because the arithmetic on actual weight produces targets nobody can eat. Harold Bays added a caution from the other room: DXA counts water as lean mass, and patients on these drugs often drink less, so some of what a scan calls muscle loss may be water.6

Speculation · extrapolation beyond the data
Weight loss has converged. At least 6 agents, approved and investigational, now report between 17% and 25%, which is too close for the next entrants to compete on the scale alone. My guess is that the next marketing contest is fought over composition: muscle-sparing, bone-protective, fat-selective. The groundwork was visible at the meeting, when 6 companies brought bone or body-composition data to a single 90-minute session. If that is where this goes, expect the claims to outrun the evidence the way weight-loss claims once did, and expect DXA to be asked to prove things it can’t. The endpoint to demand is function: stairs, chairs, walking speed. Until a trial shows patients doing more, a better-looking scan is a hypothesis.

What changes this week

  1. Quote the journal, and show the growth data with it. For children 6 to 11, that means a 13.5% BMI reduction alongside growth of 4.4 cm a year against 5.6 cm, with adult height unknown and no FDA approval for obesity under 12.

  2. Stop treating the maximum dose as the destination. A patient who is losing weight and tolerating a middle dose can stay there. When cost forces the issue, SURMOUNT-MAINTAIN shows that a lower dose holds far more than stopping does.

  3. When coverage fails, lead with what has evidence. That means a lower maintenance dose, or longer-term phentermine in the right patient, with the label, the heart rate and the narrowing gap at 2 years discussed out loud.

  4. Measure function in patients over 65. A timed sit-to-stand or a short walk test takes a minute and can be done on camera. Weight and BMI won’t show you the patient who is getting weaker.

  5. Say “attenuates.” What the trial tested was supervised resistance training 3 days a week with progressively heavier loads. That is what I’d prescribe, and I’d promise less muscle loss, not none.

  6. Move protein above the RDA. Anchor the target to adjusted body weight in severe obesity.

If you’ve lost weight and the stairs at home are getting harder, that’s something I want to hear about at follow-up. For the clinicians reading, what are you using to track function in your older patients, especially on video visits? Hit reply and tell me.

Support Substance Over Noise
Readers like you keep this going.
Other amount
The scale is the easiest thing to measure and often the least informative. At Vineyard, our clinicians treat obesity as the chronic disease it is, with attention to nutrition and strength alongside the prescription.

See how Vineyard approaches obesity care →

Following the latest GLP-1 clinical trials?

Explore the trial tracker →

Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice. He is a consultant to Viking Therapeutics and provides research consulting to Novo Nordisk, which makes semaglutide (Wegovy) and is developing CagriSema, both discussed in this issue. This issue includes a paid sponsorship for MicroVitamin+, and the author earns a commission on purchases made through its link or code. This article is educational and is not individualized medical advice. Talk with your own clinician before making changes to your care.

REFERENCES

1. Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al. Semaglutide for the treatment of obesity in children 6 to <12 years of age. N Engl J Med. Published online November 16, 2026. doi:10.1056/NEJMoa2604058 (STEP Young; NCT05726227)

2. Kelly AS, Pamidipati KC, Rachmiel M, et al. Tirzepatide in adolescents with obesity: the SURMOUNT-ADOLESCENTS randomized clinical trial. JAMA. Published online November 15, 2026. doi:10.1001/jama.2026.23420 (NCT06075667)

3. Wharton S, Broholm C, Horn D, et al. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. Lancet Diabetes Endocrinol. Published online November 14, 2026. doi:10.1016/S2213-8587(26)00275-5 (NCT06388187)

4. Finally, phentermine shows long-term efficacy and safety. Medscape Medical News; 2026 Nov 17. Available from: medscape.com [cited 2026 Nov 20]. Report of the LEAP results presented at ObesityWeek 2026 on November 16.

5. Green DJ, Haynes A, Underwood DR, et al. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nat Med. Published online November 9, 2026. doi:10.1038/s41591-026-04752-5 (T-REx)

6. Advances in weight-loss pharmacotherapy and body composition [oral abstracts 114 to 119]. Oral session presented at: ObesityWeek 2026; 2026 Nov 16; National Harbor, MD.

7. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601 (STEP TEENS; NCT04102189)

8. Novo Nordisk. Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine [press release]. PR Newswire; 2026 Nov 16. Available from: prnewswire.com [cited 2026 Nov 19].

9. Eli Lilly and Company. Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale [press release]. 2026 Nov 14. Available from: investor.lilly.com [cited 2026 Nov 19].

10. Young CB, Rives E, Gudzune KA, et al. The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: rationale, design, and baseline characteristics. Contemp Clin Trials. 2026;161:108219. doi:10.1016/j.cct.2026.108219

11. Wake Forest University Health Sciences. Long-term effectiveness of the antiobesity medication phentermine (LEAP). ClinicalTrials.gov identifier: NCT05176626. Available from: clinicaltrials.gov [cited 2026 Nov 18].

12. Wake Forest University School of Medicine. Experts available to discuss two-year trial of low-cost obesity medication phentermine [news release]. Newswise; 2026 Nov 16. Available from: newswise.com [cited 2026 Nov 19].

13. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081 (REDEFINE 1; NCT05567796)

14. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. doi:10.1016/S0140-6736(26)00656-2 (NCT06047548)

15. Dietz W, Aronne L, Cappola A. JAMA and National Academies present the future of obesity care delivery: systems, care models, and research. Session presented at: ObesityWeek 2026; 2026 Nov 17; National Harbor, MD.

16. Cappola AR, Angus DC, Ahima RS, et al. Toward a healthier future through obesity prevention and care: the JAMA Summit report on obesity. JAMA. Published online November 17, 2026. doi:10.1001/jama.2026.19759

17. Schnitzer TJ, Hunter DJ, Conaghan PG, et al. Retatrutide once weekly in adults with knee osteoarthritis pain and obesity. N Engl J Med. Published online November 8, 2026. doi:10.1056/NEJMoa2610676 (TRIUMPH-4, NCT05931367; TRIUMPH-1-OA, NCT05929066)

18. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026;395(18):1781-1793. doi:10.1056/NEJMoa2604169 (TRIUMPH-1; NCT05929066)

19. Ahn C, Roberts B, Church D. Muscle in the crosshairs: IMAT, GLP-1s, and the battle for lean mass. Session presented at: ObesityWeek 2026; 2026 Nov 16; National Harbor, MD.

20. Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15(4):310-321. doi:10.1111/obr.12143

21. Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141

Evidence-based obesity medicine, twice a week. No hype, no telehealth grifts.